What Does the Structure-function Relationship of the HIV-1 Tat Protein Teach Us About Developing an AIDS Vaccine?

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2009 May 27

PMID 19467159

Citations 45

Authors

Grant R Campbell

Erwann P Loret

Affiliations

Soon will be listed here.

Abstract

The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Tat is an important factor in viral pathogenesis. In addition to its function as the key trans-activator of viral transcription, Tat is also secreted by the infected cell and taken up by neighboring cells where it has an effect both on infected and uninfected cells. In this review we will focus on the relationship between the structure of the Tat protein and its function as a secreted factor. To this end we will summarize some of the exogenous functions of Tat that have been implicated in HIV-1 pathogenesis and the impact of structural variations and viral subtype variants of Tat on those functions. Finally, since in some patients the presence of Tat-specific antibodies or CTL frequencies are associated with slow or non-progression to AIDS, we will also discuss the role of Tat as a potential vaccine candidate, the advances made in this field, and the importance of using a Tat protein capable of eliciting a protective or therapeutic immune response to viral challenge.

Citing Articles

Molecular Characterization of Small Ruminant Lentiviruses in Sheep and Goats: A Systematic Review.

Gobbi P, Pavone S, Orso M, Passamonti F, Righi C, Beato M Animals (Basel). 2024; 14(23).

PMID: 39682510 PMC: 11640545. DOI: 10.3390/ani14233545.

Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity and Anti-SCR HIV-1 Effects.

Sadeghi L, Bolhassani A, Mohit E, Baesi K, Aghasadeghi M Curr HIV Res. 2024; 22(2):109-119.

PMID: 38712371 DOI: 10.2174/011570162X297602240430142231.

Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F Int J Mol Sci. 2024; 25(3).

PMID: 38338977 PMC: 10855115. DOI: 10.3390/ijms25031704.

PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex.

Jin J, Bai H, Yan H, Deng T, Li T, Xiao R Nat Commun. 2023; 14(1):7274.

PMID: 37949879 PMC: 10638354. DOI: 10.1038/s41467-023-43060-1.

Overview of the structure and function of the dopamine transporter and its protein interactions.

Nepal B, Das S, Reith M, Kortagere S Front Physiol. 2023; 14:1150355.

PMID: 36935752 PMC: 10020207. DOI: 10.3389/fphys.2023.1150355.

References

Hirokawa N . Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol. 1994; 6(1):74-81. DOI: 10.1016/0955-0674(94)90119-8. View

Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan R . Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993; 67(1):277-87. PMC: 237361. DOI: 10.1128/JVI.67.1.277-287.1993. View

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006; 20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc. View

Sabatier J, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A . Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol. 1991; 65(2):961-7. PMC: 239839. DOI: 10.1128/JVI.65.2.961-967.1991. View

Scott-Algara D, Truong L, Versmisse P, David A, Luong T, Nguyen N . Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. 2003; 171(11):5663-7. DOI: 10.4049/jimmunol.171.11.5663. View

Bell C, Connell B, Capovilla A, Venter W, Stevens W, Papathanasopoulos M . Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res Hum Retroviruses. 2007; 23(2):322-30. DOI: 10.1089/aid.2006.0181. View

Kaul R, Rowland-Jones S, Kimani J, Dong T, Yang H, Kiama P . Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest. 2001; 107(3):341-9. PMC: 199193. DOI: 10.1172/JCI10714. View

Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O . Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol. 2000; 6(2):145-55. DOI: 10.3109/13550280009013158. View

Opi S, Peloponese Jr J, Esquieu D, Watkins J, Campbell G, de Mareuil J . Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine. 2004; 22(23-24):3105-11. DOI: 10.1016/j.vaccine.2004.01.057. View

10.

Xiao H, Neuveut C, Tiffany H, Benkirane M, Rich E, Murphy P . Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A. 2000; 97(21):11466-71. PMC: 17223. DOI: 10.1073/pnas.97.21.11466. View

11.

Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand P . Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol. 2002; 21(9):653-8. DOI: 10.1089/104454902760330183. View

12.

Peloponese Jr J, Gregoire C, Opi S, Esquieu D, Sturgis J, Lebrun E . 1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C R Acad Sci III. 2000; 323(10):883-94. DOI: 10.1016/s0764-4469(00)01228-2. View

13.

Fiala M, Looney D, Stins M, Way D, Zhang L, Gan X . TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med. 1997; 3(8):553-64. PMC: 2230176. View

14.

Kim T, Avraham H, Koh Y, Jiang S, Park I, Avraham S . HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol. 2003; 170(5):2629-37. DOI: 10.4049/jimmunol.170.5.2629. View

15.

Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S . Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 2004; 304(5676):1500-2. DOI: 10.1126/science.1096645. View

16.

Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi M . HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A. 1998; 95(22):13153-8. PMC: 23742. DOI: 10.1073/pnas.95.22.13153. View

17.

Ensoli B, Barillari G, Salahuddin S, Gallo R, Wong-Staal F . Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990; 345(6270):84-6. DOI: 10.1038/345084a0. View

18.

Caselli E, Betti M, Grossi M, Balboni P, Rossi C, Boarini C . DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol. 1999; 162(9):5631-8. View

19.

Minghetti L, Visentin S, Patrizio M, Franchini L, Ajmone-Cat M, Levi G . Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem Res. 2004; 29(5):965-78. DOI: 10.1023/b:nere.0000021241.90133.89. View

20.

Koken S, Greijer A, Verhoef K, van Wamel J, Bukrinskaya A, Berkhout B . Intracellular analysis of in vitro modified HIV Tat protein. J Biol Chem. 1994; 269(11):8366-75. View